NGM Bio to Host Conference Call to Discuss Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call on May 24, 2021, at 8:30 a.m. ET to discuss topline results from the 24-week Phase 2b ALPINE 2/3 study.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call on May 24, 2021, at 8:30 a.m. ET to discuss topline results from the 24-week Phase 2b ALPINE 2/3 study. This study evaluates the efficacy of aldafermin in patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis. Participants will compare different doses (0.3 mg, 1 mg, and 3 mg) against a placebo. The call is open to both domestic and international callers, with archived webcasts available for 30 days.
Positive
- The upcoming conference call will provide critical topline results from the Phase 2b ALPINE 2/3 study, which could indicate the efficacy of aldafermin in treating NASH.
Negative
- None.
Details
News Market Reaction – NGM
The recorded move for NGM in the trading session of this news was -40.77%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., May 23, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, May 24, 2021 at 8:30 a.m. ET (5:30 a.m. PT) to discuss topline results from the 24-week Phase 2b ALPINE 2/3 study evaluating 0.3 mg, 1 mg and 3 mg doses of aldafermin versus placebo in patients with non-alcoholic steatohepatitis, or NASH, with stage 2 or 3 liver fibrosis. Conference call and webcast details are as follows:
Live Conference Call
Domestic Callers: (844) 873-0551
International Callers: (602) 563-8472
Passcode: 9393531
Live and Archived Webcast
For the live or archived webcast, please visit the “Investors & Media” section of NGM’s website at https://ir.ngmbio.com/. The webcast will be archived for 30 days.
Archived Conference Call
Domestic Callers: (855) 859-2056
International Callers: (404) 537-3406
Passcode: 9393531
The archived conference call will be available for 30 days.
About NGM Biopharmaceuticals, Inc.
NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases and cancer. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry. Visit us at www.ngmbio.com for more information.
| Investor Contact: Alex Schwartz ir@ngmbio.com | Media Contact: Liz Melone media@ngmbio.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.